Ranitidine Pediatric Dose — Gastrointestinal Indications
Ranitidine is an H2-receptor antagonist that reduces gastric acid secretion by competitively blocking histamine H2 receptors on parietal cells. It is used in pediatric practice for the management of conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and other acid-related gastrointestinal disorders. Clinicians should be aware of current institutional and regulatory guidance regarding ranitidine availability prior to prescribing.
Pediatric Dosing
The recommended oral dose of ranitidine in pediatric patients is 4–10 mg/kg/day PO, divided and administered every 8–12 hours, depending on clinical indication and severity.
- Dose range: 4–10 mg/kg/day PO
- Frequency: Divided every 8–12 hours
- Adult reference dose: 150 mg PO twice daily (BID)
Worked example: For a 20 kg child at the midrange dose of 7 mg/kg/day: 20 × 7 mg/kg/day = 140 mg/day, divided every 12 hours = approximately 70 mg per dose. Consult institutional protocol for maximum single-dose limits and weight-based dose capping in larger pediatric patients.
Indications and Clinical Context
Ranitidine is indicated for pediatric patients with acid-related gastrointestinal conditions, including GERD, esophagitis, and peptic ulcer disease. H2-receptor antagonists such as ranitidine reduce basal and stimulated gastric acid output, providing symptomatic relief and mucosal healing. They are commonly employed when lifestyle modifications are insufficient and may be used as an alternative or adjunct to proton pump inhibitor therapy depending on the clinical scenario and patient age.
Dosing is typically individualized within the 4–10 mg/kg/day range based on symptom severity, the specific GI diagnosis, and patient response. Standard pediatric GI guidelines support weight-based dosing with periodic reassessment of ongoing need.
Administration and Monitoring
Ranitidine is administered orally and is available in tablet and liquid formulations to accommodate different pediatric age groups. The total daily dose should be divided every 8–12 hours as clinically indicated. For patients approaching adult body weight, the adult reference dose of 150 mg BID should be used as the upper dosing ceiling; consult institutional protocol for specific dose capping thresholds.
- Monitor for headache, gastrointestinal upset (nausea, constipation, or diarrhea), and rare CNS effects (dizziness, confusion), particularly in patients with renal impairment.
- Dose adjustment may be required in patients with significant renal dysfunction.
- Assess clinical response periodically; prolonged use without reassessment is discouraged.
- Verify ranitidine availability and institutional approval prior to prescribing given prior regulatory actions regarding product quality.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.